ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to inv...

Descrición completa

Detalles Bibliográficos

Principais autores:	Shane R. Stecklein, Bruce F. Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M. Staley, Qamar J. Khan, Anne P. O’Dea, Lauren E. Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B. Pathak, Andrew K. Godwin, Priyanka Sharma
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2023-03-01
Series:	npj Breast Cancer
Acceso en liña:	https://doi.org/10.1038/s41523-023-00512-7
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!